DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



A Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty

Information source: DeNova Research
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Rhinoplasty

Intervention: ARTISS human fibrin sealant (Biological)

Phase: Phase 2

Status: Recruiting

Sponsored by: DeNova Research

Official(s) and/or principal investigator(s):
Steven H Dayan, MD, Principal Investigator, Affiliation: DeNova Research

Overall contact:
Katherine Cho, MPH, Phone: 312.335.2070, Email: katherine@denovaresearch.com

Summary

Rhinoplasty (nasal reconstruction i. e. "a nose job") is a surgical procedure performed on the nose to correct a medical problem or change the appearance of the nose. During the healing process, swelling and/or bruising is likely to occur. A drug called ARTISS Fibrin Sealant may or may not lessen these effects. This study is looking to see the effects of ARTISS on adhering tissue and improving wound healing in an external rhinoplasty. The purpose of this study is to evaluate the safety and effectiveness of rhinoplasty using ARTISS compared to rhinoplasty without using ARTISS in patients undergoing rhinoplasty performed through an external approach.

Clinical Details

Official title: A Prospective, Double-Blinded, Randomized Study Evaluating the Efficacy and Safety of ARTISS Human Fibrin Sealant as Used in External Rhinoplasty

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Outcomes Assessor), Primary Purpose: Treatment

Primary outcome:

Efficacy

The primary safety endpoint is the incidence of AEs.

Secondary outcome:

Severity of Edema

Blinded-assessment of satisfaction

Objective Ecchymosis Evaluation

Subjective Ecchymosis Evaluation

Number of Participants with Adverse Events

Subject Downtime Questionnaire

HPSS Assessment

Ease of Use

Eligibility

Minimum age: 18 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria: 1. Males and females between 18 and 65 years of age. 2. Subjects requesting primary rhinoplasty and requiring an external approach. 3. Subjects willing to undergo treatment with fibrin sealant. 4. Willingness and ability to comply with protocol requirements, including returning for follow-up visits and abstaining from exclusionary procedures for the duration of the study. 5. Willingness and ability to comply with the PI's standard preoperative and postoperative rhinoplasty instructions. 6. Subjects of childbearing potential must have a negative urine pregnancy test result at Visit 1 and be willing able to use an acceptable method of birth control (e. g., barrier methods used with a spermicidal agent, hormonal methods, IUD, surgical sterilization, abstinence) during the study. Women will not be considered of childbearing potential if one of the following is documented on the medical history:

- postmenopausal for at least 12 months prior to study drug administration

- without a uterus and/or both ovaries

- has had a bilateral tubal ligation for at least 6 months prior to study drug

administration.

- absence of an other physical condition according to the PI's discretion

7. Willingness and ability to provide written photo consent and adherence to photography procedures (i. e., removal of jewelry and makeup). 8. Willingness and ability to provide written informed consent prior to performance of any study related procedure. Exclusion Criteria: 1. Subjects who are pregnant, nursing, planning to become pregnant, and/or not using a reliable form of birth control. 2. Subjects who are planning a concurrent facial surgery during the operation (eg forehead plasty, blepharoplasty, rhinoplasty, buccal fat removal, any filler injections including fat injections, lip augmentation, skin resurfacing procedures etc.). 3. Subjects with a previous history of rhinoplasty. 4. Subjects with a current history of smoking. 5. Subjects with a previous history of a bleeding or coagulation disorder . 6. Subject with a previous history of a vascular disorder, cardiovascular disease, and/or uncontrolled hypertension. 7. Subjects a previous history of diabetes mellitus with glycosylated hemoglobin (HbA1c) > 7. 8. Subjects undergoing active treatment for a malignancy. 9. Subjects with a previous history of has a connective tissue disorder. 10. Subjects with active or chronic skin disorder. 11. Subjects with a previous history of Bell's palsy. 12. Subjects with a previous history of pathologically or pharmacologically induced immune deficiency. 13. Subjects who have received chronic treatment with immunosuppressive drugs, systemic corticosteroids, or other chronic treatments within 30 days prior to the surgery. 14. Subjects with a known sensitivity to components of FS VH S/D 4 s-apr. 15. Subjects with a previous history of healing complications following previous surgeries (eg, hypertrophic scarring). 16. Subjects with a significant systemic illness or illness localized to the areas of treatment. 17. Subjects with previous history of nasal implants. 18. Subjects with previous or current history of nasal infections. 19. Subjects who have history of blood thinners (aspirin, ibuprofen, naprosyn, herbal supplements, Vitamin E) within the two weeks prior to surgery. 20. Subjects who have smoked within the two weeks prior to surgery. 21. Subjects who have had alcohol or illicit drugs one week prior to surgery. 22. Subjects who have eaten or drank anything after midnight the night prior to surgery. 23. Subjects with current history of chronic drug or alcohol abuse. 24. Concurrent therapy that, in the investigator's opinion, would interfere with the evaluation of the safety or efficacy of the study medication. 25. Subjects who anticipate the need for surgery, other than the study procedure, or overnight hospitalization during the study. 26. Subjects who, in the Investigator's opinion, have a history of poor cooperation, non compliance with medical treatment or unreliability. 27. Subject has participated in another clinical study involving an investigational product/device within 30 days prior to enrollment or is scheduled to participate in another clinical study involving an investigational product/device during the course of this study

Locations and Contacts

Katherine Cho, MPH, Phone: 312.335.2070, Email: katherine@denovaresearch.com

DeNova Research, Chicago, Illinois 60611, United States; Recruiting
Katherine Cho, MPH, Phone: 312-335-2070, Email: katherine@denovaresearch.com
Steven H Dayan, MD, Principal Investigator
Additional Information

Starting date: November 2012
Last updated: September 12, 2014

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017